Here are Wednesday's biggest analyst calls: Nvidia, SpaceX, Apple, Tesla, Target, Amazon, Microsoft & more

Wednesday's analyst actions skewed positive, led by bullish calls on AI infrastructure: Deutsche Bank initiated FormFactor at Buy with 2028 EPS estimates about 45% above consensus, while William Blair highlighted CoreWeave's roughly $130B committed backlog and $2.58B of expected Q2 2026 revenue. Piper Sandler raised Microsoft's target to $610 from $550 after Copilot added about 10M seats sequentially, and Rosenblatt lifted Amazon's target to $360 from $335. Offsetting calls included Citi's downgrade of Moderna to Sell on valuation concerns and Morgan Stanley's forecast for Tesla Q3 2026 deliveries of 441,000, down 11% year over year.

Analysis

The actionable signal is not the aggregate analyst tone but the broadening of AI spend beneficiaries beyond GPU suppliers into test (FORM), interconnect (APH), optical components (LITE, COHR), network systems (ANET, CIEN), and manufacturing services (CLS). This supports a 6-18 month capex-cycle thesis, but also raises the risk that investors are extrapolating infrastructure orders twice: once in hyperscaler capex and again in neocloud capacity buildouts. The highest-quality exposure remains suppliers with diversified end markets and shorter working-capital cycles; leveraged GPU-cloud operators carry substantially greater financing, utilization, and customer-concentration risk if training demand shifts toward more efficient inference workloads.

AAPL's stable availability signal is more useful as a negative catalyst filter than as evidence of an upside volume surprise. Meanwhile, AMZN's ad-risk debate is likely misframed: agentic commerce could pressure paid-search discovery, but Amazon can monetize transaction intent, fulfillment, payments, and sponsored placement within agents; the key risk is margin mix and bargaining power, not an immediate collapse in advertising revenue. MSFT's monetization trajectory is the cleaner software read-through, although seat additions need to convert into durable ARPU rather than discounted bundle adoption over the next two quarters.

For consumer credit, ALLY faces a less favorable asymmetry than diversified banks because auto-credit losses, funding costs, and used-car residual values can deteriorate concurrently. Conversely, GO and TGT are potential inflation trade-down beneficiaries, but their upside depends on gross-margin execution rather than merely higher traffic; a promotional response from Walmart or Costco would quickly cap estimates. MRNA's valuation risk is real, but biotech shorts should be sized modestly because pipeline and partnership news can overwhelm fundamental downside on short horizons.

Key Decisions for Investors

• Initiate a 3-6 month long FORM / short SMH relative-value position. FORM offers more direct earnings torque to rising test complexity, while the SMH hedge limits broad semiconductor-beta risk; exit if FORM's next order commentary does not show backlog or utilization improvement.
• Own APH and CLS over CRWV and NBIS for a 6-12 month AI-infrastructure basket. Interconnect and manufacturing vendors participate in deployment regardless of which cloud provider wins, whereas GPU-cloud equity value is highly sensitive to debt financing, GPU lease economics, and utilization; reassess if hyperscaler capex guidance decelerates materially.
• Establish a 1-3 month long AMZN / short SNAP pair rather than treating agentic commerce as an Amazon advertising short. Amazon has more transaction data and monetization surfaces, while SNAP is more exposed to discretionary brand budgets; invalidate on material Amazon advertising growth deceleration or evidence of lower sponsored-product conversion.
• Maintain an underweight or tactical short ALLY versus KRE over the next two earnings cycles. The thesis requires worsening net interest margin and credit-cost guidance; cover if delinquency trends stabilize and deposit/funding costs decline faster than expected.
• Do not chase MRNA solely on the downgrade. Set an alert for a valuation rebound without corresponding clinical-data or revenue-guide improvement; only then consider defined-risk put structures, given binary pipeline-event risk.